Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Daniel E Spratt1, Sandy Srinivas2, Nabil Adra3

  • 11Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Journal of the National Comprehensive Cancer Network : JNCCN
|November 10, 2025
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

Extracellular vesicles in prostate cancer: current understanding and future perspectives.

Journal of the National Cancer Center·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Automated Assessment of Nondosimetric Aspects of Prostate Radiation Therapy Treatment Quality in a Large Plan Database.

Advances in radiation oncology·2026
Same author

Outcomes of Radiotherapy With or Without Dose Escalation to Lymph Node Metastases Detected by PET PSMA or Conventional Imaging in Node-Positive Prostate Cancer: A Real-World Multicenter Propensity Score-Matched (PRIMENOD) Analysis.

Clinical nuclear medicine·2026
Same author

High-Flow Nasal Oxygen Therapy After Cardiac Surgery: A Randomized Clinical Trial.

JAMA network open·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles
Summary
This summary is machine-generated.

The NCCN Guidelines offer a decision-making framework for prostate cancer patients, detailing treatment for metastatic castration-sensitive (mCSPC) and castration-resistant (CRPC) stages. Shared decision-making is emphasized, considering patient factors and disease characteristics for optimal care.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer management requires tailored strategies across different disease stages.
  • Current guidelines address metastatic castration-sensitive prostate cancer (mCSPC) and castration-resistant prostate cancer (CRPC).

Purpose of the Study:

  • To outline the NCCN Guidelines for prostate cancer treatment decision-making.
  • To detail therapeutic approaches for mCSPC and CRPC based on disease characteristics.

Main Methods:

  • Review of NCCN Guidelines for prostate cancer.
  • Focus on treatment considerations for mCSPC and CRPC stages.
  • Emphasis on shared decision-making principles.

Main Results:

  • Treatment decisions for mCSPC depend on metastasis timing and burden, influencing therapy intensification and directed therapies.

Related Experiment Videos

  • mCRPC management involves continuing androgen deprivation therapy with added agents like AR pathway inhibitors, chemotherapy, immunotherapy, radiopharmaceuticals, or targeted therapies.
  • NCCN panel highlights shared decision-making based on patient preferences, history, biomarkers, metastasis extent, symptoms, and side effects.

    • Conclusions:

    • The NCCN Guidelines provide a comprehensive framework for prostate cancer management.
    • Personalized treatment strategies are crucial for both mCSPC and CRPC.
    • Shared decision-making is integral to optimizing patient outcomes in prostate cancer care.